KalVista Pharmaceuticals (KALV) Competitors $14.74 +0.22 (+1.48%) As of 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KALV vs. MTSR, MOR, KYMR, IMVT, ALVO, CRNX, HCM, AMRX, CPRX, and BHCShould you be buying KalVista Pharmaceuticals stock or one of its competitors? The main competitors of KalVista Pharmaceuticals include Metsera (MTSR), MorphoSys (MOR), Kymera Therapeutics (KYMR), Immunovant (IMVT), Alvotech (ALVO), Crinetics Pharmaceuticals (CRNX), HUTCHMED (HCM), Amneal Pharmaceuticals (AMRX), Catalyst Pharmaceuticals (CPRX), and Bausch Health Cos (BHC). These companies are all part of the "pharmaceutical products" industry. KalVista Pharmaceuticals vs. Its Competitors Metsera MorphoSys Kymera Therapeutics Immunovant Alvotech Crinetics Pharmaceuticals HUTCHMED Amneal Pharmaceuticals Catalyst Pharmaceuticals Bausch Health Cos KalVista Pharmaceuticals (NASDAQ:KALV) and Metsera (NASDAQ:MTSR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends. Which has stronger earnings and valuation, KALV or MTSR? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKalVista PharmaceuticalsN/AN/A-$183.44M-$3.69-3.99MetseraN/AN/A-$209.13MN/AN/A Is KALV or MTSR more profitable? Metsera's return on equity of 0.00% beat KalVista Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets KalVista PharmaceuticalsN/A -134.07% -82.65% Metsera N/A N/A N/A Do analysts prefer KALV or MTSR? KalVista Pharmaceuticals currently has a consensus price target of $26.29, suggesting a potential upside of 78.39%. Metsera has a consensus price target of $55.00, suggesting a potential upside of 35.70%. Given KalVista Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe KalVista Pharmaceuticals is more favorable than Metsera.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score KalVista Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Metsera 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to KALV or MTSR? In the previous week, KalVista Pharmaceuticals had 33 more articles in the media than Metsera. MarketBeat recorded 39 mentions for KalVista Pharmaceuticals and 6 mentions for Metsera. Metsera's average media sentiment score of 0.72 beat KalVista Pharmaceuticals' score of 0.67 indicating that Metsera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment KalVista Pharmaceuticals 10 Very Positive mention(s) 6 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Metsera 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryKalVista Pharmaceuticals beats Metsera on 6 of the 9 factors compared between the two stocks. Get KalVista Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KALV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KALV vs. The Competition Export to ExcelMetricKalVista PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$733.02M$2.42B$5.54B$9.13BDividend YieldN/A1.81%5.06%4.01%P/E Ratio-3.989.1928.2819.59Price / SalesN/A458.26373.0879.85Price / CashN/A22.3424.7227.50Price / Book7.674.698.275.54Net Income-$183.44M$30.99M$3.19B$252.38M7 Day Performance-2.16%7.16%5.55%3.04%1 Month Performance13.70%22.28%9.36%11.67%1 Year Performance13.00%-2.75%30.22%17.14% KalVista Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KALVKalVista Pharmaceuticals4.091 of 5 stars$14.74+1.5%$26.29+78.4%+11.3%$733.02MN/A-3.98100Earnings ReportMTSRMetseraN/A$28.39-3.6%$55.00+93.7%N/A$2.98BN/A0.0081News CoverageGap DownMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730KYMRKymera Therapeutics3.127 of 5 stars$43.81-2.2%$59.11+34.9%+5.2%$2.85B$47.07M-14.13170IMVTImmunovant1.4728 of 5 stars$16.42-3.1%$38.33+133.5%-40.7%$2.81BN/A-5.99120News CoverageALVOAlvotech2.883 of 5 stars$9.02-1.8%$18.00+99.6%-29.9%$2.77B$585.60M24.381,032CRNXCrinetics Pharmaceuticals3.4651 of 5 stars$29.06-2.5%$71.75+146.9%-40.5%$2.72B$1.04M-7.61210HCMHUTCHMED1.6253 of 5 stars$15.42-2.5%$19.00+23.2%-17.3%$2.69B$630.20M0.001,811Gap DownAMRXAmneal Pharmaceuticals2.5881 of 5 stars$8.41-0.1%$11.60+37.9%+15.9%$2.64B$2.79B-210.208,100CPRXCatalyst Pharmaceuticals4.927 of 5 stars$20.95-2.4%$32.83+56.7%+31.5%$2.56B$491.73M13.3480Positive NewsBHCBausch Health Cos3.8271 of 5 stars$6.88-2.5%$7.42+7.8%-13.3%$2.55B$9.63B-62.5520,700 Related Companies and Tools Related Companies MTSR Alternatives MOR Alternatives KYMR Alternatives IMVT Alternatives ALVO Alternatives CRNX Alternatives HCM Alternatives AMRX Alternatives CPRX Alternatives BHC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KALV) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KalVista Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KalVista Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
